https://www.fiercepharma.com/pharma/not-just-another-approval-for-merck-s-keytruda-as-nice-signs-off-first-line-nsclc-indication
Keytruda scores key NICE sign-off for first-line NSCLC indication.
"Those who received Keytruda and chemotherpy lived a median 15.9 months, compared to 11.3 months for those on chemo alone, leading to a 36% reduction in the risk of death" Looks like 14 week improvement in survival.
Although this is a step forward I don't think it will be as good as an eftilagimod keytruda trial as first line treatment in this disorder.
And isn't the second line tacti 002 treatment showing better survival?
- Forums
- ASX - By Stock
- IMM
- Overnight Market report
Overnight Market report, page-104
-
-
- There are more pages in this discussion • 2,682 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $421.2M |
Open | High | Low | Value | Volume |
30.0¢ | 30.0¢ | 28.5¢ | $751.3K | 2.589M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
21 | 307462 | 28.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.5¢ | 118494 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 257462 | 0.285 |
18 | 712543 | 0.280 |
6 | 125918 | 0.275 |
11 | 273188 | 0.270 |
7 | 124774 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.295 | 118494 | 4 |
0.300 | 623600 | 3 |
0.305 | 191186 | 8 |
0.310 | 507281 | 6 |
0.315 | 138917 | 6 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online